For Healthcare Professionals Only.
Singapore, the first country in Asia to introduce Pfizer’s 20-valent pneumococcal vaccine (PCV20), initially approved it for active immunization in individuals aged 18 years and older only.1 Subsequent findings regarding its safety and immunogenicity have led to its expanded therapeutic indications, now encompassing active immunization for infants, children and adolescents aged 6 weeks to less than 18 years.2
Login to read more
